The interest in psychedelics as a therapeutic intervention for existential distress of people with terminal illness grounds on their mechanism of action and effect on the spiritual/existential aspects accompanying end-of-life experiences.
Aims:
This systematic review and network meta-analysis aimed at examining the efficacy and safety of psychedelic compounds for existential distress in terminally ill people.
Methods:
PubMed, CINAHL, PsycINFO, EMBASE, and clinicaltrials.gov were searched for randomized controlled trials (RCTs) administering psychedelics for existential distress in people with terminal illnesses. Meta-analysis estimated the standardized mean difference (SMD) and odds ratio (OR), with corresponding 95% confidence intervals (95% CI), between treated and control groups in pairwise and network comparisons, using random-effects models. Post-treatment measures of depression and anxiety, as proxies of existential distress, and tolerability were the primary outcomes.
Results:
Nine studies, involving 606 participants (362 treated with psychedelics: psilocybin, ketamine, 3,4-methylenedioxymethamphetamine, and lysergic acid diethylamide (LSD)) were included. The meta-analysis supported the efficacy of psychedelics on depression (SMD: −0.80 (95% CI: −0.98, −0.63)) and anxiety (SMD: −0.84 (95% CI: −1.20, −0.48)). Network meta-analysis identified psilocybin as the most effective compound for depression, and LSD for anxiety. However, head-to-head comparison between psychedelics did not reach statistical significance. The rates of treatment discontinuation and adverse events between psychedelics and controls were comparable.
Conclusions:
Psychedelics, especially psilocybins and LSD, showed promising effects on depression and anxiety in people with terminal illnesses. Limitations include the small number of RCTs, methodological issues related to blinding, and the lack of direct comparisons between psychedelic compounds. Larger studies and comparative research are needed to consolidate these findings.
AnDWeiCWangJ, et al (2021) Intranasal ketamine for depression in adults: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. Front Psychol12: 648691.
2.
ArrietaOAnguloLPNúñez-ValenciaC, et al (2013) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol20: 1941–1948.
3.
BahjiAVazquezGHZarateCA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord278: 542–555.
4.
Baker-GlennEAParkBGrangerL, et al (2011) Desire for psychological support in cancer patients with depression or distress: Validation of a simple help question. Psycho-oncology20: 525–531.
5.
BalduzziSRückerGNikolakopoulouA, et al (2023) Netmeta: An R package for network meta-analysis using frequentist methods. Journal of Statistical Software106: 1–40.
6.
BalduzziSRückerGSchwarzerG (2019) How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health22: 153–160.
7.
BarnettBSParkerSEWeleffJ (2022) United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. Int J Drug Policy99: 103473.
8.
BaşoğluMMarksILivanouM, et al (1997) Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. Arch Gen Psychiatry54(8): 744–748.
9.
BogenschutzMPJohnsonMW (2016) Classic hallucinogens in the treatment of addictions. Prog Neuro-Psychopharmacol Biol Psychiatry64: 250–258.
10.
BreitbartWRosenfeldBPessinH, et al (2015) Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol33: 749–754.
11.
Carhart-HarrisR (2019) How do psychedelics work?Curr Opin Psychiatry32(1): 16.
12.
Carhart-HarrisRGoodwinGM (2017) The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology42: 2105–2113.
13.
Carhart-HarrisRGiribaldiBWattsR, et al (2021) Trial of psilocybin versus escitalopram for depression. New Engl J Med384: 1402–1411.
14.
Carhart-HarrisRLBolstridgeMDayCMJ, et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology235: 399–408.
15.
ChiTGoldJA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci411: 116715.
16.
CoveyLSHuM-CWinhusenT, et al (2010) OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: Racial/ethnic differences. Drug Alcohol Depend110: 156–159.
17.
DavisAKBarrettFSMayDG, et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78(5): 481–489.
18.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–188.
19.
dos SantosRGOsórioFLCrippaJAS, et al (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol6: 193–213.
20.
DuvalSTweedieR (2000) Trim and fill: A simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics56: 455–463.
21.
FanWYangHSunY, et al (2017) Ketamine rapidly relieves acute suicidal ideation in cancer patients: A randomized controlled clinical trial. Oncotarget8: 2356–2360.
22.
FreedmanR (2010) Abrupt withdrawal of antidepressant treatment. Am J Psychiatry167: 886–888.
23.
FuentesJJFonsecaFElicesM, et al (2019) Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Front Psychiatry10: 943.
24.
GasserPHolsteinDMichelY, et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513–520.
25.
GerhardDMWohlebESDumanRS (2016) Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today21: 454–464.
26.
GillHGillBChen-LiD, et al (2020) The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother20: 1263–1273.
27.
GiribaldiBWattsRBaker-JonesM, et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med384: 1402–1411.
28.
GoelDBZilateS (2022) Potential therapeutic effects of psilocybin: A systematic review. Cureus14: e30214.
29.
GoodwinGMAaronsonSTAlvarezO, et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med387(18): 1637–1648.
30.
GoodwinGMMalievskaiaEFonzoGA, et al (2024) Must psilocybin always “assist psychotherapy”?Am J Psychiatry181: 20–25.
31.
GrabskiMBorissovaAMarshB, et al (2020) Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. Behav Brain Res392: 112629.
32.
GrassiLCarusoRHammelefK, et al (2014) Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review. Int Rev Psychiatry (Abingdon, England)26: 44–62.
33.
GriffithsRRJohnsonMWCarducciMA, et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxford, England)30: 1181–1197.
34.
GriffithsRRJohnsonMWRichardsWA, et al (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology218: 649–665.
35.
GrobCSDanforthALChopraGS, et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
36.
HartogsohnI (2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol (Oxford, England)30: 1259–1267.
37.
HigginsJPTAltmanDGGøtzschePC, et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ343: d5928.
38.
HigginsJPTJacksonDBarrettJK, et al (2012) Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res Synth Meth3: 98–110.
39.
HigginsJPTThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med21: 1539–1558.
40.
HolzeFGasserPMüllerF, et al (2023) Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry93: 215–223.
41.
HusainMIBlumbergerDMCastleDJ, et al (2023) Psilocybin for treatment-resistant depression without psychedelic effects: Study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open9: e134.
42.
InserraAPiotADe GregorioD, et al (2023) Lysergic acid diethylamide (LSD) for the treatment of anxiety disorders: Preclinical and clinical evidence. CNS Drugs37: 733–754.
43.
JacksonDBarrettJKRiceS, et al (2014) A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med33: 3639–3654.
44.
JohnsonMWRichardsWGriffithsR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol (Oxford, England)22: 603–620.
45.
KometerMSchmidtABachmannR, et al (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry72: 898–906.
46.
LeMayKWilsonKG (2008) Treatment of existential distress in life threatening illness: A review of manualized interventions. Clin Psychol Rev28: 472–493.
47.
LeyLHolzeFArikciD, et al (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology48: 1659–1667.
48.
LiXFryeMASheltonRC (2012) Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology37: 77–101.
49.
LiiTRSmithAEFlohrJR, et al (2023) Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nat Ment Health1: 876–886.
50.
LiechtiMEDolderPCSchmidY (2017) Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology234: 1499–1510.
LinY-HSahkerEShinoharaK, et al (2022) Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000–2020: A systematic review and meta-analysis. EClinicalMedicine50: 101505.
53.
LiuPLiPLiQ, et al (2021) Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. J Invest Surg34: 883–888.
54.
MacleanKALeoutsakosJ-MSJohnsonMW, et al (2012) Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig51: 721–737.
55.
MarchiMMagariniFMGalliG, et al (2022) The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: A systematic review and meta-analysis. Front Neurosci16: 1011103.
56.
MathaiDSMeyerMJStorchEA, et al (2020) The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord264: 123–129.
57.
MiladinovicBChaimaniAHozoI, et al (2014) Indirect treatment comparison. Stata J14: 76–86.
58.
MitchellAJChanMBhattiH, et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol12: 160–174.
59.
MitchellJMBogenschutzMLiliensteinA, et al (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
60.
MuttoniSArdissinoMJohnC (2019) Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord258: 11–24.
61.
NicholsDEJohnsonMWNicholsCD (2017) Psychedelics as medicines: An emerging new paradigm. Clin Pharmacol Ther101: 209–219.
62.
NuttDErritzoeDCarhart-HarrisR (2020) Psychedelic psychiatry’s brave new world. Cell181: 24–28.
63.
OlsonDEYadenDBFejerG (2021) Are the subjective effects of psychedelics necessary for their enduring therapeutic effects? A conversation with David E. Olson and David B. Yaden hosted by George Fejer. ALIUS Bulletin5: 40–57.
64.
OstuzziGMatchamFDauchyS, et al (2015) Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev2015: CD011006.
65.
PageMJMcKenzieJEBossuytPM, et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ372: n71.
66.
PahnkeWNKurlandAAUngerS, et al (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA212: 1856–1863.
67.
PhillipsJLNorrisSTalbotJ, et al (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Am J Psychiatry176: 401–409.
68.
R Core Team (2024) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org.
69.
ReynoldsLMBarnettBWeleffJ, et al (2022) The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Palliat Support Care22: 664–673.
70.
RhodesKMTurnerRMHigginsJPT (2015) Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol68: 52–60.
71.
Rivera-GarcíaMTCruzSL (2023) The resurgence of hallucinogen drugs in clinical research. Rev Invest Clin75: 169–178.
72.
RosenblatJDLeon-CarlyleMAliS, et al (2023) Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry180: 395–396.
73.
RossSBossisAGussJ, et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol (Oxford, England)30: 1165–1180.
74.
SalantiG (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Meth3: 80–97.
75.
SalantiGAdesAEIoannidisJPA (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol64: 163–171.
76.
SchimmelNBreeksemaJJSmith-ApeldoornSY, et al (2022) Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review. Psychopharmacology239: 15–33.
77.
SchlagAKAdayJSalamI, et al (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol (Oxford, England)36: 258–272.
78.
SchmidYEnzlerFGasserP, et al (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry78: 544–553.
79.
SchünemannHBrożekJGuyattG, et al (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Available at: https://gdt.gradepro.org/app/handbook/handbook.html (accessed 6 July 2022).
SessaB (2018) The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. Psychopharmacology235: 551–560.
82.
SpiegelD (2015) Existential psychotherapy for patients with advanced cancer: Facing the future and the past. J Clin Oncol33: 2713–2714.
83.
SterneJAEggerMMoherD (2008) Addressing reporting biases. In: HigginsJPTChurchillRChandlerJCumpstonMS (eds.) Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ, USA: John Wiley & Sons, Ltd, pp.297–333. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470712184.ch10 (accessed 28 January 2022).
84.
SterneJACSuttonAJIoannidisJPA, et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ343: d4002.
85.
SuttonAJDuvalSJTweedieRL, et al (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ320: 1574–1577.
86.
TajikaAFurukawaTAShinoharaK, et al (2023) Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: A systematic review. BMJ Ment Health26: e300654
87.
TerrinNSchmidCHLauJ, et al (2003) Adjusting for publication bias in the presence of heterogeneity. Stat Med22: 2113–2126.
88.
TurnerRMDaveyJClarkeMJ, et al (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol41: 818–827.
89.
VeronikiAAVasiliadisHSHigginsJPT, et al (2013) Evaluation of inconsistency in networks of interventions. Int J Epidemiol42: 332–345.
90.
WalkerJSawhneyAHansenCH, et al (2014) Treatment of depression in adults with cancer: A systematic review of randomized controlled trials. Psychol Med44: 897–907.
91.
WhiteCMWeismanNDaloJ (2023) Psychedelics for patients with cancer: A comprehensive literature review. Ann Pharmacother57: 1062–1075.
92.
WittKPottsJHubersA, et al (2020) Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry54: 29–45.
93.
WolfsonPEAndriesJFeducciaAA, et al (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep10: 20442.
94.
XuRZhanYChenS (2017) Effect of intraoperative single administration of sub-anesthesia ketamine on breast cancer patients with depression. Biomed Res-India28: 552–556.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
